Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Aptinyx
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04148391CT.gov NYX-458 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Parkinson's Disease or Lewy Body Dementia (Cognition, Memory, Attention, Thinking) | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Dementia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nevadistinel (this asset) | Aptinyx | P2 | CCC · 53 |
| Risperidone | Hannover Medical School | P4 | BBB |
| Citalopram | Hannover Medical School | P4 | BBB |
| Memantine | Zealand University Hospital | P4 | BB |
| Escitalopram | Ohio State University | P4 | BB |
| Galantamine Hydrobromide | Janssen Pharmaceutica N.V., Belgium | P3 | BB |
| Ioflupane | Mayo Clinic | P4 | BB |
| Olanzapine | Hannover Medical School | P4 | BB |
| Sertraline | Hannover Medical School | P4 | BB |
+42 more in the Dementia cohort
Other indications for Nevadistinel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lewy Body Dementia | — | P2 | CCC · 53 |
| Cognitive Disorder | — | P2 | CCC · 51 |
| Parkinson Disease | — | P2 | CCC · 48 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Nevadistinel in Dementia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nevadistinel-dementia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →